Navigation Links
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet(R)
Date:9/30/2009

PITTSBURGH, Sept. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.

Carbidopa and Levodopa Tablets are the generic version of Bristol Myers Squibb's Parkinson's treatment Sinemet®, 10mg/100mg, 25mg/100mg and 25mg/250 mg. For the 12 months ending June 30, 2009, Carbidopa and Levodopa tablets had U.S. sales of approximately $79 million for the same strengths, according to IMS Health. Mylan has launched this product.

Currently, Mylan has 123 ANDAs pending FDA approval representing $86.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $17.4 billion in annual brand sales, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
2. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
3. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
4. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
5. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
6. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
7. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
8. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
9. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
10. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
11. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  New research by the ... Institute and the U.S. Department of Health and ... Preparedness and Response (ASPR), published online today in ... pharmacy notifications encourage patients with chronic conditions to ... The study also affirms that public-private partnerships can ...
(Date:12/5/2016)... Dec. 5, 2016  BD (Becton, Dickinson and Company) ... technology company, will demonstrate an enhanced technology platform designed ... including the company,s leading Pyxis™ and Alaris™ systems, at ... 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent of ...
(Date:12/5/2016)... 5, 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... , , The global ... by 2021, at a CAGR of 5.3% from 2016 to 2021. Factors ... obesity cases, increasing government spending on healthcare, and rising income levels are ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... , ... Sideline Products is a Southern York County Pennsylvania-based premier designer and ... the horse. Smaller saddles can pinch and irritate the horse creating safety issues and ... fitted western saddle so it does not impact the comfort or performance of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Airy Jeanine ... with prolific Songwriter-Producer Corey “Chorus” Gibson who has worked on hits by mega-artists ... a few.     https://twitter.com/coreychorus , The sessions taking place in North Jersey’s ...
(Date:12/5/2016)... ... , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and Dr. Douglas ... not do their research and undergo cosmetic dermatology treatments from unqualified practitioners or worse, ... renaissance and every other month a new treatment or device is launched, promising everlasting ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
Breaking Medicine News(10 mins):